17β-estradiol and lipopolysaccharide additively promote pelvic inflammation and growth of endometriosis

Reprod Sci. 2015 May;22(5):585-94. doi: 10.1177/1933719114556487. Epub 2014 Oct 29.

Abstract

Endometriosis is a multifactorial disease mostly affecting women of reproductive age. An additive effect between inflammation and stress reaction on the growth of endometriosis has been demonstrated. Here we investigated the combined effect between 17β-estradiol (E2) and lipopolysaccharide (LPS) on pelvic inflammation and growth of endometriotic cells. Peritoneal fluid was collected from 46 women with endometriosis and 30 control women during laparoscopy. Peritoneal macrophages (Mφ) and stromal cells from eutopic/ectopic endometrial stromal cells (ESCs) were isolated from 10 women each with and without endometriosis in primary culture. Changes in cytokine secretion (interleukin 6 [IL-6] and tumor necrosis factor α [TNF-α]) by Mφ and proliferation of ESCs in response to single and combined treatment with E2 and LPS were measured by enzyme-linked immunosorbent assay and by bromodeoxyuridine incorporation assay, respectively. A significantly increased secretion of IL-6 and TNF-α in Mφ culture media was found in response to E2 (10(-8) mol/L) compared to nontreated Mφ. This effect of E2 was abrogated after pretreatment of cells with ICI 182720 (10(-6) mol/L; an estrogen receptor [ER] antagonist). Combined treatment with E2 and LPS (10 ng/mL) additively promoted IL-6 and TNF-α secretion by peritoneal Mφ and growth of eutopic/ectopic ESCs. The additive effects of E2 + LPS on cytokine secretion and growth of ESCs were effectively suppressed after combined blocking of ER and Toll-like receptor 4. An additive effect was observed between E2 and LPS on promoting proinflammatory response in pelvis and growth of endometriosis.

Keywords: LPS; endometriosis; estradiol; macrophages; stromal cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Inflammatory Agents / pharmacology
  • Case-Control Studies
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Endometriosis / drug therapy
  • Endometriosis / immunology
  • Endometriosis / metabolism*
  • Endometriosis / pathology
  • Endometrium / drug effects*
  • Endometrium / immunology
  • Endometrium / metabolism
  • Endometrium / pathology
  • Estradiol / pharmacology*
  • Estrogen Antagonists / pharmacology
  • Female
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / metabolism
  • Humans
  • Inflammation Mediators / immunology
  • Inflammation Mediators / metabolism*
  • Interleukin-6 / metabolism
  • Lipopolysaccharides / pharmacology*
  • Macrophages, Peritoneal / drug effects*
  • Macrophages, Peritoneal / immunology
  • Macrophages, Peritoneal / metabolism
  • Macrophages, Peritoneal / pathology
  • Receptors, Estrogen / drug effects
  • Receptors, Estrogen / metabolism
  • Stromal Cells / drug effects*
  • Stromal Cells / immunology
  • Stromal Cells / metabolism
  • Stromal Cells / pathology
  • Toll-Like Receptor 4 / drug effects
  • Toll-Like Receptor 4 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Estrogen Antagonists
  • IL6 protein, human
  • Inflammation Mediators
  • Interleukin-6
  • Lipopolysaccharides
  • Receptors, Estrogen
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide, Escherichia coli O111 B4
  • Gonadotropin-Releasing Hormone
  • Estradiol